{"_canonicalization":{"envelope_id":"axm_ + sha256(envelope minus {signature, axiom_id, anchors})","envelope_signature":"ed25519(envelope minus {signature, axiom_id})","json":"sort_keys=True, separators=(',',':'), ensure_ascii=False, allow_nan=False, utf-8","leaf_hash":"sha256(0x00 || canonical_json(envelope_full))","seal_signature":"ed25519(seal minus {signature, sig_algorithm})"},"axiom_id":"axm_71911f8e2740869b22eb11838502366e27cd8c0c8ca8db2148fc165d15a44b26","bitcoin_anchor":{"bitcoin_attestations":[],"calendar_attestations":[],"ots_url":"","stamped_at":"","status":"pending_next_stamp"},"envelope":{"anchors":[{"chain":"crovia.axiom_graph","height":0,"merkle_proof":"spider_vendor_press_v1","root_at_anchor":"spider_vendor_press_v1"}],"axiom_id":"axm_71911f8e2740869b22eb11838502366e27cd8c0c8ca8db2148fc165d15a44b26","axiom_type":"AX.OBS","body":{"axiom_subtype":"news.vendor_press.v1","category":"news","fingerprint":"85cea099b66a56400281f4ca2ea30e08b513a6c1cedbf5da1ebb3215e88cc6c0","published":"Wed, 03 Jun 2026 00:00:00 -0400","receipt_hash":"85cea099b66a56400281f4ca2ea30e08b513a6c1cedbf5da1ebb3215e88cc6c0","schema":"spider.news.vendor_press.v1","spider":"vendor_press","spider_record":{"axiom_subtype":"news.vendor_press.v1","category":"news","decision_hint":"POSITIVE","envelope_target":"AX.OBS","fingerprint":"85cea099b66a56400281f4ca2ea30e08b513a6c1cedbf5da1ebb3215e88cc6c0","observed_at":"2026-06-03T04:43:57.136784Z","parent_run_hash":"62ae9c8eda846b00bc49666345b338d00756c5203438666c4c1fc694cc364b84","published":"Wed, 03 Jun 2026 00:00:00 -0400","runtime_version":"0.1.0","schema":"spider.news.vendor_press.v1","source_status":200,"source_url":"https://export.arxiv.org/rss/cs.AI","spider":"vendor_press","summary_excerpt":"arXiv:2606.00555v2 Announce Type: replace \nAbstract: Structure-based drug design increasingly employs LLM agents to iteratively refine ligands against a target pocket, yet a viable ligand must satisfy two often-conflicting objectives -- binding affinity and druggability -- which single optimization steps rarely improve together. To quantify this difficulty, we introduce two diagnostic metrics: the first measures how often a single edit improves both objectives, and the second measures how often a gain on one objective comes with a loss on the other. Applying these diagnostics to current LLM-agent pipelines exposes a consistent failure mode: the agent performs molecular editing without knowing how the pocket-ligand complex responds to local modifications, thus rarely achieving joint improvement. Inspired by medicinal chemists, who probe the pocket-ligand complex with controlled analog edits before choosing an optimization direction, we propose \\textbf{PROBE}, an optimization framework b","title":"Probe Before You Edit: Probing-Guided Molecular Optimization for LLM Agents in Structure-Based Drug Design","url":"https://arxiv.org/abs/2606.00555","vendor":"arxiv_cs_ai"},"summary":"arXiv:2606.00555v2 Announce Type: replace \nAbstract: Structure-based drug design increasingly employs LLM agents to iteratively refine ligands against a target pocket, yet a viable ligand must satisfy two often-conflicting objectives -- binding affinity and druggability -- which single optimization steps rarely improve together. To quantify this difficulty, we introduce two diagnostic metrics: the first measures how often a single edit improves both objectives, and the second measures how often a gain on one objective comes with a loss on the other. Applying these diagnostics to current LLM-agent pipelines exposes a consistent failure mode: the agent performs molecular editing without knowing how the pocket-ligand complex responds to local modifications, thus rarely achieving joint improvement. Inspired by medicinal chemists, who probe the pocket-ligand complex with controlled analog edits before choosing an optimization direction, we propose \\textbf{PROBE}, an optimization framework b","title":"Probe Before You Edit: Probing-Guided Molecular Optimization for LLM Agents in Structure-Based Drug Design","vendor":"arxiv_cs_ai"},"confidence":{"method":"deterministic"},"decision":"POSITIVE","issued_at":"2026-06-03T04:43:57Z","notes":"Spider vendor_press (news) news.vendor_press.v1","object":{"captured_by":"crovia.spider.vendor_press","primary_source_url":"https://arxiv.org/abs/2606.00555"},"predecessors":[],"schema":"crovia.axiom.v1","signature":"ed25519:8e16b47687b2ef419db727aa5f98632a9afcde3d99a5f318c89b0dd63409df4fc858f3d1f9fcf0c58ca7c03bb2689efaf836745d38c9c6350aea3029a050ed0e","signer":"crovia.substrate","subject":{"observed_at":"2026-06-03T04:43:57Z","source_collector":"spider:vendor_press","target_id":"https://arxiv.org/abs/2606.00555"},"tsa":{"authority":"crovia.substrate.bootstrap","rfc3161_token":"{\"kind\":\"crovia.bootstrap.tsa\",\"source_jsonl\":\"/opt/crovia/spider/data/news/vendor_press_v1.jsonl\",\"source_seal_merkle_root\":\"spider_vendor_press_v1\",\"upgrade_path\":\"Sessione H \\u2014 OpenTimestamps weekly anchor\"}"},"zk_mode":"clear","zk_proof":null},"ledger":{"leaf_hash":"dbf46ae241b8c1c87772aa3de2810d0ce7100f878c8c21af8aba9b3942466360","leaf_index":209330,"ledger_path":"/opt/crovia/substrate/axiom_ledger.jsonl"},"merkle_proof":{"hash_alg":"sha256","leaf_prefix":"0x00","node_prefix":"0x01","odd_leaf_rule":"duplicate_last","path":[{"sibling":"5589e00a1ff5f94eaafb8536f267fa8b802080ea1785b743bd6d08f7ba5fa979","side":"right"},{"sibling":"b6b8816f7f8c1ff4663dcbddf9173cf97ee6db9e9d0fedf3032d65d8d7c296ff","side":"left"},{"sibling":"6c292bc82e0151e2702c21ddb9e42b74f371fc2ae56479553473807e4f8b3248","side":"right"},{"sibling":"bd4b8391c510c9c1417c159b53f83a5ba2a6aeb6bd86cba4d01630cc4e48d2ba","side":"right"},{"sibling":"d1d3330fb955b3c8d5fa71bad6b0df3cdd41176cce6f0da94f83827e118645f4","side":"left"},{"sibling":"0ee55be4f19504f49b1520a00b7c41813b27148ebdf7c2099670dc547019fccb","side":"left"},{"sibling":"4a9041cff48b223827c44d2d56d150c595450d4a6390b4eb331519bc36b634f1","side":"right"},{"sibling":"768ffa75e0a020ca1e4038beeef0da5c26e64a7ba3a0528188d49b4d35664067","side":"left"},{"sibling":"2b9867040ec52d22722edc26b204e15651723dcc66d361cc1af11490a854d461","side":"left"},{"sibling":"2abcec6d14b256f82b270a3141886de6129141dec525543607b760f02588a877","side":"right"},{"sibling":"2b6b45743f97ac502854e489ac38a3366f8ae7ede58a2728b45daadbf29e9d03","side":"right"},{"sibling":"a81babbd79ea0da9e030dd7f43bffb6519d214317decd50727bea4e78189d970","side":"right"},{"sibling":"2dca509b3eb767a47cf215d4315f230ce9103a76264412008ae23a349b519ef1","side":"left"},{"sibling":"24d1bb4b13e0e46131b27b70a48e65fcf4e2e14b95e3bb83ade821e9df530f6b","side":"left"},{"sibling":"8d3baa674a45fd8bc6d3e8d25298f4bec86c72fa8259d576c330d12955c7b4f7","side":"right"},{"sibling":"e32819d1eff909db08066d1703f2db3f091cddac19378b2c0c625ab11e3fdbc0","side":"right"},{"sibling":"c300cf0154c136afc09b1702a0be98f4ba5b6dc5cf57e8cc714ec1eaf4196eff","side":"left"},{"sibling":"d841ad93efda0869e5eb97678f348f03f5caab4353e05ff4bf18f47fb945b822","side":"left"}]},"schema":"crovia.axiom_proof.v1","seal":{"first_collector_run_id":"","first_receipt_hash":"","jsonl_path":"/opt/crovia/substrate/axiom_ledger.jsonl","key_id":"430895f101d38164","last_collector_run_id":"","last_receipt_hash":"","leaf_count":209569,"merkle_root":"c852efc8ad7dfffc196c71380f79e6398bcaf566974cbae7c9950b0f600d5bc8","public_key_hex":"cf742e26f75669dc673cb5c0786a1ae23ae8ca19c347317192ce40c28a7ff25c","run_id":"hourly_json_retrofit_20260603T053701Z","schema":"crovia.seal.v1","seal_family_version":"crovia-seal-family/1","seal_kind":"substrate_batch","sealed_at":"2026-06-03T05:37:57Z","sig_algorithm":"ed25519","signature":"1ca417607effc813341721cfdade0a2d2d4ba96a90d361dbc3e864b6991b90abc326ec41d9ba3e7110cc04adb29d7b8d95abea7ff2ab8c591b2f864ed7270c03","signer_version":"1.1.0"},"trust_root":{"key_id":"430895f101d38164","public_key_hex":"cf742e26f75669dc673cb5c0786a1ae23ae8ca19c347317192ce40c28a7ff25c","signature_algorithm":"ed25519","url":"/registry/canon/TRUST_ROOT.md"},"verifier":{"spec":"/registry/canon/AXIOM_RECEIPT_v1.md","url":"/v/axm_71911f8e2740869b22eb11838502366e27cd8c0c8ca8db2148fc165d15a44b26"}}